On 17 October 2003, orphan designation (EU/3/03/171) was granted by the European Commission to PharmaMar S.A., Spain, for trabectedin for the treatment of ovarian cancer.
Ecteinascidin 743 in treatment of ovarian cancer has been authorised in the EU as Yondelis since 28 October 2009.
Treatment of ovarian cancer
|Date of designation||
|Orphan designation status||
|EU designation number||
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see: